Inozyme gets $67mm via Series A2

Inozyme Pharma Inc. (developing therapies for rare diseases of calcification) raised $67mm in its Series A2 financing led by Pivotal bioVenture Partners and Sofinnova Investments, which were joined by RA Capital Management, Cowen Healthcare Investments, and Rock Springs Capital, and returning shareholders Longitude Capital, New Enterprise Associates, Novo Holdings, and Sanofi Ventures. Inozyme will use the funds to move its lead enzyme replacement therapy INZ701 into the clinic for severe conditions associated with deficiencies in the enzyme ENPP1, including generalized arterial calcification of infancy and autosomal recessive hypophosphatemic Rickets Type 2. The company is also exploring development of INZ701 for ABCC6 deficiency.